ArticleInternational journal of hematology2025
The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperleukocytosis is defined as a white blood cell (WBC) count ≥ 100,000/mm MATERIAL AND
methodsThis retrospective study included 40 pediatric patients (< 18 years) with acute leukemia and hyperleukocytosis at presentation. Patients were monitored for TLS development, and groups that received and did not receive leukapheresis were compared. Statistical analyses were performed using IBM SPSS 22.
resultsOf 40 patients, 32.5% (n = 13) underwent leukapheresis. TLS occurred in 47.5% (n = 19) of patients, with no statistically significant difference between groups (p = 0.44). No leukapheresis patients required hemodialysis, while four non-leukapheresis patients did. Time from presentation to chemotherapy initiation was not significantly different between groups (p = 0.10).
conclusionWhile leukapheresis did not significantly affect the incidence of TLS, clinical improvements were observed in some patients, particularly in hyperleukocytosis-related symptoms, such as respiratory distress and neurological manifestations. These findings suggest that leukapheresis may play a supportive role in managing leukostasis-associated complications in pediatric acute leukemia patients presenting with hyperleukocytosis.
Indexed as
Identifiers
40586951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.